Pfizer’s resurrection in the obesity market took its next step Tuesday.
The pharma firm said that an experimental weight loss drug, recently picked up through Pfizer’s contested acquisition of the biotech Metsera, hit its marks in a mid-stage study, demonstrating the potential to be a once-a-month treatment.
Investors, however, will be parsing the data to assess how they compare to outcomes offered by other drugs in the increasingly competitive obesity market. Pfizer’s share price was flat in pre-market trading.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply